We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.15B
AUM Growth
-$403M
Cap. Flow
-$229M
Cap. Flow %
-3.73%
Top 10 Hldgs %
39.96%
Holding
178
New
9
Increased
64
Reduced
62
Closed
12

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$35.2M
2
SYK icon
Stryker
SYK
+$32.7M
3
UNH icon
UnitedHealth
UNH
+$27.9M
4
PODD icon
Insulet
PODD
+$25.5M
5
RMD icon
ResMed
RMD
+$25.5M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$56.7M
2
ARGX icon
argenx
ARGX
+$45.6M
3
INSM icon
Insmed
INSM
+$43.4M
4
BSX icon
Boston Scientific
BSX
+$42.4M
5
HUM icon
Humana
HUM
+$36.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Industrials 0.05%
3 Communication Services 0.02%
4 Technology 0.02%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDNA icon
26
CareDx
CDNA
$2.05B
$60.8M 0.99%
3,912,575
-21,431
-0.5% -$259K
ELV icon
27
Elevance Health
ELV
$80.9B
$55M 0.89%
101,549
+2,937
+3% +$1.55M
PEN icon
28
Penumbra
PEN
$12.5B
$50.8M 0.82%
282,049
+100,891
+56% +$20.1M
EXAS
29
DELISTED
Exact Sciences
EXAS
$49M 0.8%
1,158,880
+20,354
+2% +$1.12M
ZBH icon
30
Zimmer Biomet
ZBH
$17.6B
$48.7M 0.79%
449,081
+166,864
+59% +$19.7M
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$48.5M 0.79%
4,464,693
-851
-0% -$10.9K
CRL icon
32
Charles River Laboratories
CRL
$10.8B
$48.1M 0.78%
232,702
+3,005
+1% +$681K
IDXX icon
33
Idexx Laboratories
IDXX
$44.8B
$45.5M 0.74%
93,358
– –
LLY icon
34
Eli Lilly
LLY
$1.05T
$45M 0.73%
49,674
-8,291
-14% -$6.63M
BIO icon
35
Bio-Rad Laboratories Class A
BIO
$8.15B
$42.4M 0.69%
155,258
-1,360
-0.9% -$396K
MGNX icon
36
MacroGenics
MGNX
$285M
$42.3M 0.69%
9,942,313
-23,549
-0.2% -$229K
AXSM icon
37
Axsome Therapeutics
AXSM
$11.8B
$41.6M 0.68%
516,533
-168,943
-25% -$12.5M
RLAY icon
38
Relay Therapeutics
RLAY
$4.34B
$41.6M 0.68%
6,377,115
+450,497
+8% +$3.08M
EPIX
39
DELISTED
ESSA Pharma
EPIX
$41.5M 0.67%
7,889,583
– –
PRCT icon
40
Procept Biorobotics
PRCT
$1.09B
$40.9M 0.66%
669,049
-221,065
-25% -$13.1M
CI icon
41
Cigna
CI
$74.5B
$40.7M 0.66%
123,090
+43,445
+55% +$15M
GEHC icon
42
GE HealthCare
GEHC
$28.7B
$40.6M 0.66%
521,017
+8,787
+2% +$717K
EXEL icon
43
Exelixis
EXEL
$14.1B
$40.5M 0.66%
1,803,200
-100,000
-5% -$2.22M
SRPT icon
44
Sarepta Therapeutics
SRPT
$1.82B
$39.9M 0.65%
252,321
+800
+0.3% +$103K
BDTX icon
45
Black Diamond Therapeutics
BDTX
$103M
$39.7M 0.65%
8,517,839
– –
HCA icon
46
HCA Healthcare
HCA
$82.3B
$39.3M 0.64%
122,304
-37,399
-23% -$12.2M
OPCH icon
47
Option Care Health
OPCH
$3.41B
$39.2M 0.64%
1,416,879
-450,384
-24% -$13.4M
IMCR icon
48
Immunocore
IMCR
$1.78B
$39.1M 0.64%
1,154,654
+182,400
+19% +$9.3M
ALGN icon
49
Align Technology
ALGN
$12.7B
$34.8M 0.56%
143,982
-10,927
-7% -$3.04M
COO icon
50
Cooper Companies
COO
$14B
$34.7M 0.56%
397,373
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2024 Portfolio in Review

As of Q2 2024, Bellevue Group held 178 positions worth $6.15B, down 6.1% from $6.56B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $229M in Q2 2024, closing 12 positions and reducing 62 holdings. Its most notable exit was Shockwave Medical, Inc. Common Stock, an estimated $34.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Communication Services.

Against the trend, Bellevue Group opened a new position in Edgewise Therapeutics worth $25.7M.

  • Bellevue Group's largest Q2 2024 buy was Edgewise Therapeutics: 1,428,929 shares worth $25.7M.
  • Bellevue Group added most to Biohaven in Q2 2024, an estimated $35.2M increase.
  • Bellevue Group's biggest Q2 2024 reduction was Intuitive Surgical, cutting an estimated $56.7M.
  • Bellevue Group fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $34.4M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.15B portfolio in Q2 2024.
  • Bellevue Group opened 9 new positions and closed 12 in Q2 2024.
  • Bellevue Group's portfolio value fell 6.1% quarter-over-quarter to $6.15B.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.